Literature DB >> 25365093

Scores for all seasons: SDAI and CDAI.

J S Smolen1, D Aletaha.   

Abstract

Disease activity assessment is one of the most pivotal aspects in the care of RA patients. Composite measures of disease activity are superior to individual measures, since they capture the multiple facets of the disease. Since swollen joint counts correlate with joint damage progression and tender joint counts with physical function, composite scores that include joint counts are preferable. The simplified and clinical disease activity indices (SDAI, CDAI) are easy to calculate and correlate well with joint damage and physical function. Cutpoints for disease activity states have been established and improvement criteria likewise. The SDAI and CDAI remission criteria (ACR-EULAR index-based remission) are stringent, usually associated with a halt of progression of damage and optimisation of physical function and can still be achieved in 1 of 4 clinic patients and up to one third of patients in trials of early arthritis.

Entities:  

Mesh:

Year:  2014        PMID: 25365093

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  22 in total

1.  Musculoskeletal ultrasound in monitoring response to apremilast in psoriatic arthritis patients: results from a longitudinal study.

Authors:  Fulvia Ceccarelli; Ramona Lucchetti; Carlo Perricone; Francesca Romana Spinelli; Enrica Cipriano; Simona Truglia; Francesca Miranda; Valeria Riccieri; Manuela Di Franco; Rossana Scrivo; Cristiano Alessandri; Guido Valesini; Fabrizio Conti
Journal:  Clin Rheumatol       Date:  2019-07-17       Impact factor: 2.980

2.  The Structured Delegation of Medical Care Services for Patients With Inflammatory Rheumatic Diseases.

Authors:  Dietmar Krause; Anna Mai; Robin Denz; Johannes Johow; Jens-Peter Reese; Benjamin Westerhoff; Renate Klaaßen-Mielke; Nina Timmesfeld; Annette Rittstieg; Ertan Saracbasi-Zender; Judith Günzel; Claudia Klink; Elmar Schmitz; Claas Fendler; Wolf Raub; Stephanie Böddeker; Friedrich Dybowski; Georg Hübner; Hans-Jürgen Menne; Heinz-Jürgen Lakomek; Michael Sarholz; Ulrike Trampisch; Hans J Trampisch; Jürgen Braun
Journal:  Dtsch Arztebl Int       Date:  2022-03-11       Impact factor: 8.251

Review 3.  Developing new therapeutic approaches for rheumatoid arthritis: the continuing challenges of clinical assessments.

Authors:  David L Scott
Journal:  F1000Res       Date:  2016-08-17

4.  Head-to-head comparison of aggressive conventional therapy and three biological treatments and comparison of two de-escalation strategies in patients who respond to treatment: study protocol for a multicenter, randomized, open-label, blinded-assessor, phase 4 study.

Authors:  Daniel Glinatsi; Marte S Heiberg; Anna Rudin; Dan Nordström; Espen A Haavardsholm; Bjorn Gudbjornsson; Mikkel Østergaard; Till Uhlig; Gerdur Grondal; Kim Hørslev-Petersen; Ronald van Vollenhoven; Merete L Hetland
Journal:  Trials       Date:  2017-04-04       Impact factor: 2.279

5.  Effectiveness of a telemonitoring intensive strategy in early rheumatoid arthritis: comparison with the conventional management approach.

Authors:  Fausto Salaffi; Marina Carotti; Alessandro Ciapetti; Marco Di Carlo; Stefania Gasparini; Sonia Farah; Marwin Gutierrez
Journal:  BMC Musculoskelet Disord       Date:  2016-04-02       Impact factor: 2.362

Review 6.  Cardiovascular risk assessment in rheumatoid arthritis - controversies and the new approach.

Authors:  Krzysztof Bonek; Piotr Głuszko
Journal:  Reumatologia       Date:  2016-07-18

7.  The soluble cytoplasmic tail of CD45 (ct-CD45) in human plasma contributes to keep T cells in a quiescent state.

Authors:  Alexander Puck; Stefan Hopf; Madhura Modak; Otto Majdic; Petra Cejka; Stephan Blüml; Klaus Schmetterer; Catharina Arnold-Schrauf; Jens G Gerwien; Klaus S Frederiksen; Elisabeth Thell; Judith Leitner; Peter Steinberger; Regina Aigner; Maria Seyerl-Jiresch; Gerhard J Zlabinger; Johannes Stöckl
Journal:  Eur J Immunol       Date:  2016-10-31       Impact factor: 5.532

8.  Chromosome conformation signatures define predictive markers of inadequate response to methotrexate in early rheumatoid arthritis.

Authors:  Claudio Carini; Ewan Hunter; Aroul S Ramadass; Jayne Green; Alexandre Akoulitchev; Iain B McInnes; Carl S Goodyear
Journal:  J Transl Med       Date:  2018-01-29       Impact factor: 5.531

9.  Interleukin-10-producing LAG3+ regulatory T cells are associated with disease activity and abatacept treatment in rheumatoid arthritis.

Authors:  Shinichiro Nakachi; Shuji Sumitomo; Yumi Tsuchida; Haruka Tsuchiya; Masanori Kono; Rika Kato; Keiichi Sakurai; Norio Hanata; Yasuo Nagafuchi; Shoko Tateishi; Hiroko Kanda; Tomohisa Okamura; Kazuhiko Yamamoto; Keishi Fujio
Journal:  Arthritis Res Ther       Date:  2017-05-16       Impact factor: 5.156

Review 10.  Clinical, Imaging, and Pathological Suppression of Synovitis in Rheumatoid Arthritis: Is the Disease Curable?

Authors:  Serena Bugatti; Garifallia Sakellariou; Terenzj Luvaro; Maria Immacolata Greco; Antonio Manzo
Journal:  Front Med (Lausanne)       Date:  2018-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.